Nektar Therapeutics is a leading biopharmaceutical company developing a robust pipeline of novel therapeutics based on its advanced polymer conjugate chemistry technology platform. Nektar also partners with the top biopharmaceutical companies to bring new products to market. To date, Nektar's technology and drug development expertise have enabled seven approved products for partners, which include leading biopharmaceutical companies.

News
Apr 9, 2014 Nektar Reports Positive Preclinical Data for Two Oncology Programs at 2014 AACR »
Feb 26, 2014 Nektar Therapeutics Reports Fourth Quarter and Year-End 2013 Financial Results »
Feb 19, 2014 Nektar to Announce Financial Results for the Fourth Quarter and Year-End of 2013 on Wednesday, February 26, 2014, After Close of U.S.-Based Financial Markets »
Jan 22, 2014 Nektar Therapeutics Prices Public Offering of Common Stock »
Contact Nektar investor relations
Jennifer Ruddock
Vice President of Investor Relations and Corporate Affairs
415-482-5585

Jodi Sievers
Associate Director, Investor & Corporate Communications
415-482-5593

Contact
Transfer Agent and Stockholder Services
Computershare Shareholder Services
P.O. Box 43006
Providence, RI 02940-3006
(877)290-2261
(201)680-6578
www.computershare.com/investor
 
 
Site Map Privacy Terms of Use Compliance Policy Trademarks Site Users Guide